Morgan Stanley Mustang Bio, Inc. Transaction History

Morgan Stanley

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.35 - $0.72 $43,432 - $89,346	-124,092 Reduced 44.91%	152,233 $56,000
Q4 2022 Feb 14, 2023	SELL	$0.32 - $8.27 $6,379 - $164,862	-19,935 Reduced 6.73%	276,325 $107,000
Q3 2022 Nov 14, 2022	SELL	$0.46 - $7.2 $13,121 - $205,387	-28,526 Reduced 8.78%	296,260 $139,000
Q2 2022 Oct 27, 2022	BUY	$0.58 - $1.13 $37,524 - $73,107	64,697 Added 24.87%	324,786 $190,000
Q2 2022 Aug 15, 2022	BUY	$0.58 - $1.13 $37,524 - $73,107	64,697 Added 24.87%	324,786 $190,000
Q1 2022 Oct 27, 2022	SELL	$0.73 - $1.81 $47,228 - $117,101	-64,697 Reduced 19.92%	260,089 $263,000
Q1 2022 May 13, 2022	BUY	$0.73 - $1.81 $13,099 - $32,478	17,944 Added 7.41%	260,089 $263,000
Q4 2021 Feb 14, 2022	SELL	$1.66 - $2.64 $41,352 - $65,765	-24,911 Reduced 9.33%	242,145 $402,000
Q3 2021 Nov 15, 2021	BUY	$2.58 - $3.36 $689,004 - $897,308	267,056 New	267,056 $718,000

415K

Ticker MBIO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,222,000
Market Cap $27.4M
Description
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.